Juvéderm Voluma XC

El primer y único relleno aprobado por la FDA para el área facial media.

voluma

INDICACIÓN
El único relleno aprobado por la FDA para corregir la pérdida de volumen relacionada con la edad en el área facial media. Esto crea un perfil y apariencia más suave y más joven.

FÓRMULA
La tecnología VYCROSSTM produce un gel eficiente con enlaces cruzados fuertes, el cual contribuye a su capacidad de elevación y duración.

DURACIÓN
Provee un aspecto natural y suave instantáneamente, elevando el área facial media y durando hasta 2 años con tratamiento óptimo.

Dr. Montes, pionero de Juvéderm Voluma XC en Puerto Rico
puede decirte si Voluma es adecuado para ti.

amfast certification montes

Juvéderm Voluma XC Approval Marks Significant Advance in Aesthetic Medicine
The FDA in October 2013 approved Juvéderm Voluma XC (Allergan), the first injectable filler approved to temporarily correct age-related volume loss in the cheek area in adults over the age of 21.

The approval represents a significant step forward in the world of aesthetic injectable treatments for a number of reasons.

In the past we’ve looked at fillers more from the standpoint of filling in the lines, starting with collagen-based fillers and eventually hyaluronic acids.

Over the last several years, however, injectors and researchers have increasingly looked at fillers in terms of replacing volume. As we age, we lose volume, and we see that most pronounced is the mid-facial cheek area. If you look at a youthful face, one of the first things you notice is the volume of the cheek bone area.

The study that led to the approval of Juvéderm Voluma was a large multicenter trial in which researchers developed and used a validated scale, the MFVDS (mid face volume deficit scale), to account for issues clinicians encounter daily in practice.

The trial involved live patient assessments which will set the precedent for how future trials in aesthetics will be. In addition to patient assessments, there were two blinded investigators who had to come to consensus, which further validated results shown in the study.

In the trial, Juvéderm Voluma XC yielded efficacious and durable results, with patients’ mid-facial areas experiencing volumization for up to a year.

That is due an advanced manufacturing process—known as VYCROSS technology—that results in a smooth gel that flows easily and consistently.

From a more scientific standpoint the approval of Voluma will challenge physicians to continue learning about the utility of fillers, specifically regarding the developing concept of layering.

As we learn to place some products more deeply, others moderately, and others superficially, the availability of a complex volumizing agent such as this will set forth a whole new approach and open up new concepts pathways for mid-face volumization.

That’s why this approval is one of the major advances in aesthethics over the last few years.